Orfenadrina

Quick links to important sections

Orfenadrina

Method of action: Miorelaxant

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orfenadrina

Quick Facts

Property Description
Active ingredient Orphenadrine (Citrate or Hydrochloride)
Form Oral Tablets, Injectable Solution
Pharmacological class Centrally Acting Skeletal Muscle Relaxant, Anticholinergic Agent
Common use Relief of Acute Muscle Spasm and Stiffness
Origin Synthetic, Diphenhydramine Derivative

What Type of Medicine is Orfenadrina? (Classification and Composition)

Orfenadrina is a prescription medicine entity whose active compound is Orphenadrine, most commonly utilized as the citrate or hydrochloride salt, and is classified as a Centrally Acting Skeletal Muscle Relaxant. This classification defines the drug's core action, indicating it functions by modulating the central nervous system signals rather than by acting directly on muscle tissue. Orphenadrine is a synthetic compound, chemically derived from the first-generation antihistamine Diphenhydramine.

It is available for systemic administration in various dosage forms, including different oral tablets (such as standard and extended-release formulations) and a sterile injectable solution (used for intravenous or intramuscular routes). The drug may be supplied either as a single active ingredient product, such as the brand Norflex in the United States, or in fixed-combination products (e.g., with non-opioid analgesics like aspirin). The overall chemical structure of Orphenadrine imparts secondary anticholinergic properties. This indicates that Orphenadrine affects the balance of chemical messengers in the nervous system, contributing to its muscle-relaxing effect.


How Does Orfenadrina Generally Help with Muscle Discomfort? (High-Level Mechanism and Purpose)

The primary therapeutic purpose of Orfenadrina is to help provide relief from the discomfort and stiffness associated with acute muscle spasm by calming the excessive nerve impulses that sustain muscle rigidity. This effect is achieved through its central action, which helps to modulate nerve communication related to muscle tone and tension within the brain and spinal cord. It is typically used as an adjunct to rest and physical therapy. This reflects that the drug’s role is to supplement other standard methods used to manage painful muscle issues.

The benefit of this centralized action is the easing of muscle tightness and the associated discomfort. This functionality defines its role in managing musculoskeletal issues—such as the pain and stiffness following a minor strain—where the relief of tension is paramount to restoring comfort and facilitating improved physical function. This mechanism of signal modulation provides the foundation for its general utility without detailing specific conditions or administrative instructions.

Regulatory References

  1. Orphenadrine LiverTox Monograph

What side effects are possible with Orfenadrina?

Possible Side Effects and Safety Information

The official safety profile for Orphenadrine (Orfenadrina) is classified by regulatory authorities based primarily on its mild anticholinergic and central nervous system (CNS) effects. These effects define the drug’s potential side effects and necessary restrictions.

Adverse reactions are usually associated with higher dosage and often resolve upon reduction in dosage. Dryness of the mouth is commonly the first adverse effect to appear.

Documented Adverse Reaction Groupings

The side effects listed in regulatory labeling are grouped by the affected system:

  • Anticholinergic/CNS: Includes dryness of the mouth, blurred vision, dizziness, drowsiness, headache, light-headedness, constipation, and urinary retention.
  • Cardiac Disorders: Tachycardia, palpitation, and cardiac arrhythmias. Use requires caution in patients with pre-existing cardiac conditions.
  • Psychiatric: May include mental confusion (notably in older adults), excitement, or euphoria.

Serious Adverse Reactions and Risk Context

Official documents note rare occurrences of severe reactions. Anaphylactic reaction has been documented in rare instances, particularly with the injectable form. Aplastic anemia has been reported in very rare cases with the tablet form; however, regulatory documents state that no causal relationship has been established.

Population and Duration Safety

  • Older Adults: This population may experience some degree of mental confusion more frequently and are generally more susceptible to anticholinergic side effects.
  • Long-Term Use: The safety of continuous long-term therapy has not been established. Periodic monitoring of blood, urine, and liver function is recommended if treatment is prolonged.
  • Ability Impairment: Because Orphenadrine can cause light-headedness or dizziness, it may impair the ability to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle.

Use is contraindicated in patients with conditions sensitive to anticholinergic effects, including glaucoma, myasthenia gravis, and certain obstructive conditions of the gastrointestinal or urinary tracts.

Overdose and Emergency Response

Overdose and when to seek help

Orphenadrine is officially documented as toxic in overdose and primarily induces a profile characterized by severe anticholinergic effects. The range of toxicity is variable and unpredictable, requiring a high degree of caution.

Manifestations and Severe Outcomes

Documented clinical signs of overdose involve central nervous system (CNS), cardiovascular, and ocular systems. Early manifestations include confusion, delirium, hallucinations, drowsiness, blurred vision, and signs like tachycardia and urinary retention.

A severe overdose is associated with life-threatening outcomes such as seizures, severe cardiac arrhythmias, hypotension, and respiratory failure or coma. These severe manifestations establish the necessity for urgent care.

Emergency Actions Required by Regulators

Due to the drug’s potential for severe systemic effects, regulatory authorities mandate that individuals seek emergency medical attention immediately and contact a Poison Control Center at the first suspicion of overexposure.

Official Management Protocols

No specific antidote for Orphenadrine intoxication has been established. Official management is therefore symptomatic and supportive. This includes intensive monitoring (such as serial cardiac monitoring and ECG) and, when deemed necessary, procedures like evacuation of stomach contents and the use of activated charcoal.

Therapeutic Uses of Orfenadrina

Orfenadrina is commonly used in conditions characterized by acute or disruptive symptom patterns, primarily involving muscle tension and discomfort. It is utilized when supportive symptom management is appropriate, particularly in clinical settings involving physical measures.

The medication is commonly used to help with symptomatic relief for acute, painful muscle spasms, easing musculoskeletal stiffness and rigidity, and supporting specific motor symptoms associated with Parkinsonism. The medication is applied in contexts where pronounced symptoms of muscle tightness interfere with daily function. The overall benefit provides support that helps ease the overall symptom burden, and assists with maintaining functional stability in situations where symptoms interfere with routine activities. It is relevant for easing symptom clusters that may become intense or disruptive, particularly in short-term scenarios like muscle sprains or strains.


Supportive Focus: Symptom Management

Symptom Targeted Common Context Symptomatic Support
Acute Muscle Spasm Following minor strains or sprains Contributes to easing overall symptom load
Muscle Stiffness Restricted motion due to tension Assists with maintaining functional stability
Neurological Tremor Associated with Parkinsonism Is used for managing symptom intensity

Regulatory References

  1. NIH DailyMed for Orphenadrine Citrate

Eligibility and Restrictions for Use

Who Can and Cannot Use Orfenadrina?

Official regulatory documents define strict criteria for the use of Orfenadrina (Orphenadrine) based on age, existing medical conditions, and physiological status. This medication is primarily established for use in the adult population.

Absolute Non-Eligibility (Contraindications)

Use is contraindicated and officially prohibited in patients with certain conditions related to the drug's anticholinergic properties, including glaucoma, myasthenia gravis, and a known hypersensitivity to the active ingredient. Non-eligibility also extends to specific obstructive conditions of the gastrointestinal and urinary tracts, such as pyloric or duodenal obstruction, stenosing peptic ulcers, and bladder neck obstruction.

Age and Status Restrictions

Safety and effectiveness have not been established in the pediatric population; therefore, use is generally not recommended in children. Older adults require caution due to increased risk of specific effects. For pregnant patients, the drug is classified as FDA Pregnancy Category C, limiting its use. It is also generally not recommended during lactation as excretion into human milk is not known. Use requires caution in patients with pre-existing cardiac conditions or impaired hepatic or renal function.

What should I know about interactions with other medicines?

The official interaction profile for Orfenadrina is defined by its potential for additive pharmacological effects and its influence on the body’s clearance of other medicines.

Pharmacodynamic and CNS Interactions

The co-administration of Orfenadrina with other Central Nervous System (CNS) depressants, including alcohol, is associated with an additive effect, which increases the risk of drowsiness and dizziness. This potentiation also occurs with other anticholinergic agents (such as certain antidepressants or antihistamines), enhancing effects like constipation. Regulatory documentation notes a specific risk when combined with Propoxyphene, which may result in documented confusion, anxiety, and tremors.

Metabolic and Exposure Alterations

Pharmacokinetically, Orfenadrina is documented to induce the enzymatic systems responsible for metabolizing certain co-administered drugs. This pattern reduces the exposure (plasma levels) of substances like Steroidal Contraceptives, Griseofulvin, and Hexobarbital. Additionally, the drug's effect on reduced gastric motility may alter the rate of absorption of other orally administered medications. Caution is advised by regulators when the drug is used in patients with hepatic or renal impairment, and elderly patients are noted as being particularly susceptible to anticholinergic activity.

Mechanism of Action

Orphenadrine is a centrally acting agent that modulates neuronal activity through multiple distinct receptor and pathway systems within the central nervous system (CNS).


Central Anticholinergic Modulation

Orphenadrine functions as a nonselective muscarinic acetylcholine receptor (mAChR) antagonist. This binding action regulates cholinergic-driven processes, particularly in motor pathways within the brain. Antagonism of the mAChR results in a decrease in excessive cholinergic stimulation, contributing to the modulation of neuromuscular signaling activity.


NMDA Receptor Antagonism

The compound also engages pathways associated with neuronal excitation by acting as an N-methyl-D-aspartate (NMDA) receptor antagonist. By interacting with the NMDA receptor complex, the drug inhibits ion channel function. This suppression of excitatory glutamatergic signaling contributes to the overall modulation of neuronal excitability.


Reuptake Inhibition and Channel Blockade

Additional targets contribute to its pharmacodynamic profile, including weak norepinephrine and dopamine reuptake inhibition ( NDRI) and the blockade of specific sodium and potassium ion channels. These mechanisms influence the concentration and activity of specific neurotransmitters and include histamine H1 receptor binding and voltage-gated sodium channel blockade.

Dosage and Administration Information

Orphenadrine is administered via two primary routes: the oral route, using tablet forms, and the parenteral route, which includes intramuscular (IM) and intravenous (IV) injection.

Administration Patterns and Dosing

The specific usage regimen is determined by the dosage form. The extended-release oral tablets are typically prescribed at 100 mg and administered twice daily, usually in the morning and evening. The standard-dose 50 mg immediate-release form is typically taken three times a day. When administered via injection for acute situations, the standard dose is 60 mg and may be repeated every 12 hours as deemed necessary.

Key instructions for proper use include the requirement that extended-release tablets be swallowed whole and must not be crushed or chewed. Intravenous injection is subject to a procedural constraint, requiring administration slowly over approximately 5 minutes, with the recipient remaining in a supine position during and immediately following the injection.

Constraints on Use

The medication is used as an adjunct to rest and physical therapy. A critical constraint on its application is that the safety of its continuous long-term therapy has not been established. Furthermore, regarding the pediatric population, the safety and effectiveness for use in children have not been established, and use in this age group is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Orfenadrina


Evidence for Use in Acute Musculoskeletal Pain and Spasm

The research exploring Orfenadrina's use in acute painful musculoskeletal conditions includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies typically included adult populations with conditions such as low back pain or muscle spasms. Trials primarily monitored patient-reported outcomes describing perceived discomfort and functional ability metrics. Studies reported measurements of short-term outcomes related to pain intensity scores and functional scores, which were assessed during the study period and compared to the results from placebo groups or other studied compounds. Research highlights that follow-up durations were limited, focusing heavily on the immediate, acute phase. Systematic reviews note that the quality of the evidence varies, meaning there is limited information for long-term outcomes.


Evidence for Use in Managing Parkinsonism Motor Symptoms

Orfenadrina was also evaluated in research contexts involving fluctuating symptoms related to Parkinsonism. The research primarily stems from older Controlled Clinical Trials. Studies focused on populations with mild symptoms of Parkinson's disease, particularly those whose conditions were marked by functional limitations such as tremor or rigidity. Findings indicate that studies explored how symptoms evolved in the observed populations, contributing to the broader evidence landscape for anticholinergic medicines used for certain motor symptoms. However, the majority of the supporting evidence is historical. Contemporary, high-quality RCTs are less available compared to other medicines in this area.


What Remains Unclear or Under-Researched

A primary area of uncertainty across all studied indications is the variable evidence quality and limited information for long-term outcomes. Research highlights that subgroup findings are uncertain, meaning it is difficult to determine if reported observations apply consistently across different patient characteristics. Furthermore, comparative evidence is lacking in modern trials against the newest therapeutic options for chronic conditions. These gaps mean that while studies contribute to the broader evidence landscape, they provide limited insights into the comprehensive, long-term impact on daily functioning.

Key Studies & References

  1. Orphenadrine Citrate Extended Release Tablets Label - NIH DailyMed

Frequently Asked Questions (FAQ)

Common questions about Orfenadrina (FAQ)


Q: How quickly does Orfenadrina start working after taking it?

Official pharmacokinetic studies indicate that the concentration of Orfenadrina in the bloodstream typically peaks within 1 to 3 hours after taking the oral tablet. This data suggests when the medicine's maximum initial effect may be reached.

Q: How long does the effect of Orfenadrina usually last?

Official pharmacological information reports that Orfenadrina has an elimination half-life of approximately 14 hours. The half-life is a measure used to guide the appropriate frequency of doses, but the total duration of the medicine's effect can vary from person to person.

Q: Does Orfenadrina affect blood pressure?

Regulatory documents indicate that Orfenadrina can cause cardiac effects such as tachycardia (a fast heartbeat) and palpitation. While a change in blood pressure is not listed as a primary side effect, official regulatory documents define the need for caution when used by individuals with existing heart conditions.

Q: Can you take Orfenadrina with over-the-counter pain relievers like acetaminophen or ibuprofen?

Official drug information does not suggest a major interaction between Orfenadrina and common over-the-counter pain relievers like acetaminophen or ibuprofen. However, due to the possibility of additive effects with other medicines, the product information indicates that review by a healthcare provider is generally necessary before combining prescription and non-prescription drugs.

Q: What happens if I miss a dose of Orfenadrina?

Official protocol describes that if a dose is missed, it is generally taken as soon as it is remembered. If it is close to the time for the next dose, the protocol states to skip the missed dose and continue with the regular schedule. The official instructions caution against taking two doses at the same time to compensate for a skipped dose.

Q: Is Orfenadrina considered an addictive medication?

Official regulatory warnings note that Orfenadrina has the potential to be habit-forming. The label constraints indicate that the medicine must be used exactly as prescribed by a healthcare provider and is not to be shared with others.

Q: Is Orfenadrina available in a generic version?

Yes, the active ingredient, Orphenadrine (available as citrate or hydrochloride salt), is available in generic forms.

Q: Does Orfenadrina help with nerve pain?

Official documents state that Orfenadrina is indicated as an adjunct to rest and physical therapy for the relief of discomfort associated with acute painful musculoskeletal conditions and muscle spasm. It is not specifically indicated for the treatment of general nerve pain.

Q: Does food change the way Orfenadrina is absorbed?

According to official product information, there are no known specific interactions or restrictions between Orfenadrina and foods or drinks. The medicine may therefore be taken with or without food.

Q: What are the possible signs of using too much Orfenadrina?

Signs of taking too much Orfenadrina can include feelings of light-headedness, confusion, agitation, tremors, hallucinations, or a pounding heartbeat. In situations where an overdose is suspected, official sources state that immediate emergency medical attention is required.

Q: Is Orfenadrina a controlled substance in the U.S. or U.K.?

According to U.S. regulatory schedules, Orfenadrina is not classified as a controlled substance. Classification status may vary by country.

Q: Are there any specific warnings about taking Orfenadrina during hot weather?

Official information notes that Orfenadrina has anticholinergic properties, which can potentially lead to reduced sweating. Because this can affect the body's ability to regulate its temperature, official sources indicate that caution is generally necessary in situations that may lead to overheating.

Q: What is the difference between orphenadrine citrate and orphenadrine hydrochloride?

Orphenadrine is supplied as two different chemical salts: citrate and hydrochloride. The citrate salt is the form primarily described for use as a muscle relaxant. The hydrochloride salt has been historically studied for the symptomatic treatment of Parkinsonism.

Q: Is there evidence that Orfenadrina helps with chronic pain?

Official regulatory documents specify that Orfenadrina is only approved for acute use. The safety of continuous long-term therapy has not been established, and clinical trials focus on short-term outcomes for acute muscle conditions, not chronic pain management.

How should Orfenadrina be stored and disposed of?

Storage and Disposal of Orphenadrine

Official Storage Conditions

Orphenadrine tablets and injection must be stored at Controlled Room Temperature, defined as 20° to 25°C (68° to 77°F), with allowable fluctuations up to 30 C (86°F).

  • Environmental Protection: The product must be protected from light, excess heat, and moisture. It should not be stored in the bathroom.
  • Container Rules: The medication must be kept in a tight, light-resistant container that is tightly closed. The injection should remain in its original carton for light protection.
  • Child Safety: It is mandatory to KEEP OUT OF THE REACH OF CHILDREN and use a child-resistant closure for dispensing.

Disposal Requirements

Unused or expired orphenadrine must be disposed of in accordance with Federal, State, and Local regulations. The recommended method is to use an official drug take-back location. Spilled material must be collected and prevented from entering soil, drains, and waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Orfenadrina found in:

A-Z Index: